Experimental drug aims to tame rare liver disease

NCT ID NCT05104853

Completed Disease control Sponsor: COUR Pharmaceutical Development Company, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called CNP-104 in 42 adults with primary biliary cholangitis, a rare liver disease, who did not get better with standard treatments. The drug is designed to calm the immune system's attack on the bile ducts. The main goals were to check safety and see if it could lower liver damage markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CNP-104 (a peptide-based immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for people with primary biliary cholangitis who do not respond to current medications.
What could go wrong: This is an early-phase trial with only 42 participants, so results may not apply to everyone. The treatment may not improve liver function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary biliary cholangitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY BILIARY CHOLANGITIS

Contacts and locations

Locations

Cleveland Clinic - Florida

Weston, Florida, 33331, United States
Digestive Healthcare of Georgia

Atlanta, Georgia, 30309, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Florida Research Institute

Lakewood Rch, Florida, 34211-4930, United States
GI PROS Research

Naples, Florida, 34102, United States
Henry Ford Health System

Novi, Michigan, 48377, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Florida

Jacksonville, Florida, 32224, United States
Montefiore Medical Center

The Bronx, New York, 10467, United States
OM Research

Lancaster, California, 93534, United States
Peak Gastroenterology Associates

Colorado Springs, Colorado, 80907, United States
Southern California Research Center

Coronado, California, 92118, United States
Texas Liver Institute

San Antonio, Texas, 78215, United States
University of California Davis Health

Sacramento, California, 95817, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of Florida - Hepatology Research

Gainesville, Florida, 32610, United States
University of Virginia

Charlottesville, Virginia, 22903, United States
Washington University School of Medicine in St. Louis

St Louis, Missouri, 63110, United States
Yale School of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.